Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000022151 | SCV000790462 | likely pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2017-03-21 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000729821 | SCV000857512 | pathogenic | not provided | 2017-10-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000022151 | SCV001214301 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2023-12-25 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 6 of the GALT gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GALT are known to be pathogenic (PMID: 22944367). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with galactosemia (PMID: 22944367). ClinVar contains an entry for this variant (Variation ID: 25215). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Mayo Clinic Laboratories, |
RCV000729821 | SCV004226592 | pathogenic | not provided | 2023-05-23 | criteria provided, single submitter | clinical testing | PP4, PM2, PM3, PS4_moderate, PVS1_strong |
Natera, |
RCV001271240 | SCV001452284 | pathogenic | Galactosemia | 2020-09-16 | no assertion criteria provided | clinical testing |